Two separate mid-stage immunology readouts reshaped investor and competitive dynamics in atopic dermatitis. Evommune reported that EVO‑301, its IL‑18–binding fusion protein, achieved a statistically significant improvement in EASI scores in a Phase IIa trial, supporting further development. Nektar disclosed one‑year follow-up data showing its IL‑2–targeting candidate rezpegaldesleukin maintained and deepened clinical responses when moved to maintenance dosing, with high proportions of patients sustaining EASI‑75 responses. Both companies argue their mechanisms could address patients who remain uncontrolled on current standards of care. The results renew pressure on incumbents such as Sanofi/Regeneron’s Dupixent and widen the field of emerging biologics and dosing strategies being evaluated for durable control and dosing frequency advantages.